Experimental drug targets recurrent brain cancer in small early trial
NCT ID NCT05557292
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 21 times
Summary
This early-stage study tested a new drug called RMC-5552 in 7 adults whose glioblastoma (a type of brain cancer) had returned after standard treatment. The drug works by blocking a protein that helps cancer cells grow. The main goals were to find the safest dose and see if the drug could shrink tumors or slow the disease. The trial was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States
Conditions
Explore the condition pages connected to this study.